参考文献/References:
[1] Thiele S,Mantovani G,Barlier A,et al.From pseudohypoparathyroidism to inactivating PTH/PTHrP signalling disorder(iPPSD),a novel classification proposed by the EuroPHP network[J].Eur J Endocrinol,2016,175(6):P1-P17.DOI:10.1530/EJE-16-0107.
[2] Chu X,Zhu Y,Wang O,et al.Clinical and genetic characteristics of pseudohypoparathyroidism in the Chinese population[J].Clin Endocrinol(Oxf),2018,88(2):285-294.DOI:10.1111/cen.13516.
[3] Mantovani G,de Sanctis L,Barbieri AM,et al.Pseudohypoparathyroidism and GNAS epigenetic defects:clinical evaluation of albright hereditary osteodystrophy and molecular analysis in 40 patients[J].J Clin Endocrinol Metab,2010,95:651-658.DOI:10.1210/jc.2009-0176.
[4] Mantovani G,Bastepe M,Monk D,et al.Diagnosis and management of pseudohypoparathyroidism and related disorders:first international Consensus Statement[J].Nat Rev Endocrinol,2018,14(8):476-500.DOI:10.1038/s41574-018-0042-0.
[5] Li YL,Han T,Hong F.Cutaneous nodules and a novel GNAS mutation in a Chinese boy with pseudohypoparathyroidism type Ia:a case report and review of literature[J].World J Clin Cases,2020,8(3):587-593.DOI:10.12998/wjcc.v8.i3.587.
[6] Brancatella A,Mantovani G,Elli FM,et al.A severe inactivating PTH/PTHrP signaling disorder type 2 in a patient carrying a novel large deletion of the GNAS gene:a case report and review of the literature[J].Endocrine,2020,67(10):466-472.DOI:10.1007/s12020-020-02195-7.
[7] Lemos MC,Thakker RV.GNAS mutations in pseudohypoparathyroidism type 1a and related disorders[J].Hum Mutat,2015,36(1):11-9.DOI:10.1002/humu.22696.
[8] 马瑜瑾,刘鹏,袁园,等.1b型假性甲状旁腺功能减退症临床及基因甲基化分析[J].中华内分泌代谢杂志,2019,35(12):1001-1005.DOI:10.3760/cma.j.issn.1000-6699.2019.12.002.
[9] Elli FM,Bordogna P,Arosio M,et al.Mosaicism for GNAS methylation defects associated with pseudohypoparathyroidism type 1B arose in early post-zygotic phases[J].Clin Epigenetics,2018,10:16.DOI:10.1186/s13148-018-0449-4.
[10] Elli FM,de Sanctis L,Bollati V,et al.Quantitative analysis of methylation defects and correlation with clinical characteristics in patients with pseudohypoparathyroidism type I and GNAS epigenetic alterations[J].J Clin Endocrinol Metab,2014,99(3):E508-17.DOI:10.1210/jc.2013-3086.
[11] Turan S,Fernandez-Rebollo E,Aydin C,et al.Postnatal establishment of allelic Gαs silencing as a plausible explanation for delayed onset of parathyroid hormone resistance owing to heterozygous Gαs disruption[J].J Bone Miner Res,2014,29(3):749-760.DOI:10.1002/jbmr.2070.
[12] Germain-Lee EL.Management of pseudohypoparathyroidism[J].Curr Opin Pediatr,2019,31(4):537-549.DOI:10.1097/MOP.0000000000000783.
[13] Yang Y,Chu X,Nie M,et al.A novel long-range deletion spanning STX16 and NPEPL1 causing imprinting defects of the GNAS locus discovered in a patient with autosomal-dominant pseudohypoparathyroidism type 1B[J].Endocrine,2020,69(1):212-219.DOI:10.1007/s12020-020-02304-6.
[14] Elli FM,Bordogna P,Arosio M,et al.Mosaicism for GNAS methylation defects associated with pseudohypoparathyroidism type 1B arose in early post-zygotic phases[J].Clin Epigenetics,2018,10:16.DOI:10.1186/s13148-018-0449-4.
[15] Snanoudj S,Molin A,Colson C,et al.Maternal transmission ratio distortion of GNAS Loss-of-Function mutations[J].J Bone Miner Res,2020,35(5):913-919.DOI:10.1002/jbmr.3948.
[16] Mantovani G,Bastepe M,Monk D,et al.Recommendations for Diagnosis and Treatment of Pseudohypoparathyroidism and Related Disorders:An Updated Practical Tool for Physicians and Patients[J].Horm Res Paediatr,2020,93(3):182-196.DOI:10.1159/000508985.
[17] Germain-Lee EL.Management of pseudohypoparathyroidism[J].Curr Opin Pediatr,2019,31(4):537-549.DOI:10.1097/MOP.0000000000000783.
[18] Linglart A,Levine MA,Jüppner H.Pseudohypoparathyroidism[J].Endocrinol Metab Clin North Am,2018,47(4):865-888.DOI:10.1016/j.ecl.2018.07.011.
[19] Garin I,Mantovani G,Aguirre U,et al.European guidance for the molecular diagnosis of pseudohypoparathyroidism not caused by point genetic variants at GNAS:an EQA study[J].Eur J Hum Genet,2015,23(4):438-444.DOI:10.1038/ejhg.2014.127.